Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

Thi Huyen Tram Nguyen; Jérémie Guedj; Xavier Anglaret; Cédric Laouénan; Vincent Madelain; Anne-Marie Taburet; Sylvain Baize; Daouda Sissoko; Boris Pastorino; Anne Rodallec; Géraldine Piorkowski; Sara Carazo; Mamoudou N. Conde; Jean-Luc Gala; Joseph Akoi Bore; Caroline Carbonnelle; Frédéric Jacquot; Hervé Raoul; Denis Malvy; Xavier de Lamballerie; France Mentré; on behalf of the JIKI study group

首页> 外文期刊>PLOS Neglected Tropical Diseases >Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

【24h】

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

机译：JIKI试验的埃博拉感染患者中的Favipiravir药代动力学显示浓度低于目标浓度

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background In 2014–2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for this indication and that high concentrations of the drugs were needed to achieve antiviral efficacy against EBOV, a pharmacokinetic model had been used to propose relevant dosing regimen. Here we report the favipiravir plasma concentrations that were achieved in participants in the JIKI trial and put them in perspective with the model-based targeted concentrations.

机译：背景资料在2014–2015年，我们评估了几内亚对依巴韦病毒（EBOV）病（EVD）患者的依法比韦韦耐受性和疗效（JIKI试验）。由于该药物以前从未使用过，并且需要高浓度的药物才能达到针对EBOV的抗病毒功效，因此已使用药代动力学模型来提出相关的给药方案。在这里，我们报告了JIKI试验参与者达到的favipiravir血浆浓度，并将其与基于模型的目标浓度进行了比较。

著录项

来源
《PLOS Neglected Tropical Diseases》 |2017年第2期|共18页
作者
Thi Huyen Tram Nguyen; Jérémie Guedj; Xavier Anglaret; Cédric Laouénan; Vincent Madelain; Anne-Marie Taburet; Sylvain Baize; Daouda Sissoko; Boris Pastorino; Anne Rodallec; Géraldine Piorkowski; Sara Carazo; Mamoudou N. Conde; Jean-Luc Gala; Joseph Akoi Bore; Caroline Carbonnelle; Frédéric Jacquot; Hervé Raoul; Denis Malvy; Xavier de Lamballerie; France Mentré; on behalf of the JIKI study group;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类传染病;
关键词

相似文献

外文文献
中文文献
专利

1. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea [J] . Daouda Sissoko, Cedric Laouenan, Elin Folkesson, PLoS Medicine . 2016,第3期

机译：对埃博拉病毒疾病的FaviPiraviR（Jiki试验）的实验治疗：几内亚历史上控制的单臂概念试验
2. Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. [J] . Morse GD, Reichman RC, Fischl MA, Antiviral Research . 2000,第1期

机译：艾滋病毒感染患者甲磺酸依维地汀的浓度靶向I期试验：剂量要求和药代动力学研究。 ACTG 187和199研究团队。
3. Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial. [J] . Goldwirt L, Braun J, de Castro N, Antimicrobial agents and chemotherapy. . 2011,第7期

机译：从恩夫韦肽改为拉格韦韦可降低达那那韦和替拉那韦的血浆浓度：EASIER-ANRS 138试验的药代动力学子研究。
4. HPLC-MS/MS Quantification of Targeted Neuropeptides in Tac1~(-/-) Mouse Spinal Cords Reveals Significantly Lower Concentrations of Opioid Peptides [C] . Mouna Saidi, Francis Beaudry ASMS Conference on Mass Spectrometry and Allied Topics . 2015

机译：HPLC-MS / MS定量TAC1〜（/ - / - ）小鼠脊髓靶神经肽的定量显示出显着较低的阿片类药物肽浓度
5. Male Circumcision as a Bio-medical HIV Intervention Targeting Male Heterosexual Sexually Transmitted Disease (STD) Patients in China - An Acceptability Study and a Single-arm Test-of-concept Trial. [D] . Wang, Zixin. 2013

机译：男性包皮环切术作为针对中国男性异性恋性传播疾病（STD）患者的生物医学HIV干预-可接受性研究和单臂概念测试试验。
6. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted [O] . Thi Huyen Tram Nguyen, Jérémie Guedj, Xavier Anglaret, 2017

机译：JIKI试验的埃博拉感染患者中的Favipiravir药代动力学显示浓度低于目标浓度
7. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. [O] . Thi Huyen Tram Nguyen, Jérémie Guedj, Xavier Anglaret, 2017

机译：在JIKI试验的埃博拉病毒感染患者中的Favipiravir药代动力学显示浓度低于目标。

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

摘要

著录项

相似文献

相关主题

期刊订阅